1. Home
  2. HURA vs TSQ Comparison

HURA vs TSQ Comparison

Compare HURA & TSQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HURA
  • TSQ
  • Stock Information
  • Founded
  • HURA 2009
  • TSQ 1996
  • Country
  • HURA United States
  • TSQ United States
  • Employees
  • HURA N/A
  • TSQ N/A
  • Industry
  • HURA
  • TSQ Broadcasting
  • Sector
  • HURA
  • TSQ Consumer Discretionary
  • Exchange
  • HURA Nasdaq
  • TSQ Nasdaq
  • Market Cap
  • HURA 126.1M
  • TSQ 110.8M
  • IPO Year
  • HURA N/A
  • TSQ 2000
  • Fundamental
  • Price
  • HURA $2.59
  • TSQ $6.33
  • Analyst Decision
  • HURA Strong Buy
  • TSQ Buy
  • Analyst Count
  • HURA 2
  • TSQ 1
  • Target Price
  • HURA $11.50
  • TSQ $13.00
  • AVG Volume (30 Days)
  • HURA 214.3K
  • TSQ 44.3K
  • Earning Date
  • HURA 11-13-2025
  • TSQ 11-10-2025
  • Dividend Yield
  • HURA N/A
  • TSQ 12.74%
  • EPS Growth
  • HURA N/A
  • TSQ N/A
  • EPS
  • HURA N/A
  • TSQ 2.23
  • Revenue
  • HURA N/A
  • TSQ $447,247,000.00
  • Revenue This Year
  • HURA N/A
  • TSQ N/A
  • Revenue Next Year
  • HURA N/A
  • TSQ $4.47
  • P/E Ratio
  • HURA N/A
  • TSQ $2.82
  • Revenue Growth
  • HURA N/A
  • TSQ N/A
  • 52 Week Low
  • HURA $1.80
  • TSQ $6.23
  • 52 Week High
  • HURA $8.40
  • TSQ $10.79
  • Technical
  • Relative Strength Index (RSI)
  • HURA 45.68
  • TSQ 28.53
  • Support Level
  • HURA $2.38
  • TSQ $6.73
  • Resistance Level
  • HURA $2.66
  • TSQ $6.68
  • Average True Range (ATR)
  • HURA 0.12
  • TSQ 0.21
  • MACD
  • HURA 0.01
  • TSQ -0.05
  • Stochastic Oscillator
  • HURA 42.86
  • TSQ 0.00

About HURA TuHURA Biosciences Inc. Common Stock

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

About TSQ Townsquare Media Inc.

Townsquare Media Inc is a radio, digital media, entertainment, and digital marketing solutions company principally focused on being the premier local advertising and marketing solutions platform in small and mid-sized markets across the United States. It has three segments which are Subscription Digital Marketing Solutions, Digital Advertising, and Broadcast Advertising. It earns the majority of the revenue from the Broadcasting Advertising segment, which includes its local, regional, and national advertising products and solutions delivered via terrestrial radio broadcast. Its portfolio includes local media brands such as WYRK.com, WJON.com, and NJ101.5.com, and premier national music brands such as XXLmag.com, TasteofCountry.com, UltimateClassicRock.com, and Loudwire.com.

Share on Social Networks: